In brief
Researchers have developed a novel pill combining two anti-parasitic drugs that could prove effective against intestinal worms, impacting 1.5 billion people worldwide. With a focus on overcoming drug resistance and enhancing mass treatment approaches, the new medication is primarily aimed at children in affected regions.
A new mango-flavored pill designed to combat intestinal worm infections is showing encouraging results in clinical trials, potentially transforming treatment for a condition that impacts approximately 1.5 billion people worldwide. The pill is a synergistic blend of two established anti-parasitic medications, which together have demonstrated superior efficacy against these pervasive parasites, according to researchers.Intestinal worms, also known as soil-transmitted helminths (STHs), are largely transmitted through contaminated food or water and can lead to severe gastrointestinal issues, malnutrition, and anemia. Being particularly prevalent in under-resourced areas with inadequate sanitation, these infections mostly affect children. Current preventive measures are limited, primarily focusing on improved hygiene and sanitation.The recent trial, dubbed "ALIVE," is documented in the esteemed journal The Lancet and indicates that the new pill could be a significant step towards achieving the World Health Organization's objectives of eliminating STH-related diseases. Administered in a straightforward manner—either as one single dose or across three consecutive days—the pill aims to facilitate large-scale mass treatment initiatives.According to project leader Professor Jose Muñoz, the simplicity of administering a single-pill dose contributes significantly to its appeal. By combining two drugs that function under different mechanisms, the researchers also hope to diminish the likelihood of the bacteria developing resistance to treatment.Although albendazole, one of the drugs currently used, effectively treats some species of STHs, resistance has been rising. In trials conducted involving 1,001 children aged 5 to 18 from Ethiopia, Kenya, and Mozambique, the combination exhibited higher efficacy when paired with ivermectin. However, the researchers acknowledge the need for further study to ascertain its effectiveness against specific types, such as threadworm.Expert in parasitology Dr. Hany Elsheikha from the University of Nottingham considers the new pill a promising enhancement to existing treatments for various parasites. He cautions, however, that the study still has "gaps" and the findings may not translate identically across diverse age groups or regions.The results of these preliminary trials have been submitted for regulatory review in Europe and Africa, with decisions anticipated by early 2025. Meanwhile, additional clinical trials are in the works, aiming to involve 20,000 participants in Kenya and Ghana.Dr. Stella Kepha from the Kenya Medical Research Institute underscored the pill’s potential to significantly benefit impacted communities while emphasizing that more effort is required to effectively scale the treatment across regions afflicted by these intestinal worms.
